Clarivate plc has released a new report, "Mainland China Biopharma Innovation 2.0: from rapid growth to quality-driven development," highlighting a significant shift in Mainland China's biopharmaceutical industry. The analysis reveals that Mainland China has become the world's second-largest market for the first launches of new molecular entities, accounting for an 18% global share in 2024. The report details the sector's transformation from rapid expansion to a phase characterized by sustainable, quality-focused growth and greater global recognition. It also notes that between 2019 and 2023, 66% of new active substances approved by major global regulators were also approved in Mainland China, reflecting the country's increasing integration with global pharmaceutical markets. Out-licensing deals by Chinese biopharma innovators have reached $50 billion, underscoring the nation's growing influence on global healthcare innovation. The analysis is based on Clarivate's proprietary databases and a robust evaluation framework developed in partnership with Healthcare Executive.